Imaging AI firm Brainomix is highlighting clinical results regarding its 360 e-Lung technology at the American College of Chest Physicians' (ACCP) CHEST conference in Chicago.
A study conducted by researchers at the University of Chicago, Weill Cornell Medical Center in New York, and the University of Alabama at Birmingham showed that e-Lung could have supported an earlier diagnosis of progressive pulmonary fibrosis in 62% of patients and up to 21 months earlier, according to the firm. It also found that e-Lung identified disease progression on CT in 77% of patients who had been deemed clinically stable, Brainomix said.
e-Lung consists of thousands of CT scans from academic institutions, according to the firm. It was cleared by the U.S. Food and Drug Administration (FDA) in 2024.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
